Asthma and COPD Drugs Market

ID: MRFR/Pharma/7277-CR
149 Pages
Satyendra Maurya
Last Updated: April 15, 2026
Asthma and COPD Drugs Market Research Report: Size, Share, Trend Analysis By Drug Class (Bronchodilators, Corticosteroids, Combination Drugs, Leukotriene Modifiers), By Route of Administration (Inhalation, Oral, Injection, Nasal), By Applications (Asthma, Chronic Obstructive Pulmonary Disease, Allergic Rhinitis, Pulmonary Hypertension), By Patient Group (Adult, Pediatric, Geriatric) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035
Asthma and COPD Drugs Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)3.2%
2024 Market Size$ 35.35 Billion
2025 Market Size$ 36.48 Billion
2035 Market Size$ 49.99 Billion
Key Players
Companies such as GlaxoSmithKline
Boehringer Ingelheim
AstraZeneca
Novartis
Teva Pharmaceutical Industries
Merck & Co.
Trends
  • Rise of Biologics
  • Digital Health Integration
  • Focus on Preventive Care
Opportunities
  • Advancements in Drug Delivery Systems
  • Rising Awareness and Education Initiatives
  • Regulatory Support for Innovative Therapies
Summary Table of Contents Segmentation Download PDF
  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
    1. 1.1 EXECUTIVE SUMMARY | |
      1. 1.1.1 Market Overview | |
      2. 1.1.2 Key Findings | |
      3. 1.1.3 Market Segmentation | |
      4. 1.1.4 Competitive Landscape | |
      5. 1.1.5 Challenges and Opportunities | |
      6. 1.1.6 Future Outlook 2
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
    1. 2.1 MARKET INTRODUCTION | |
      1. 2.1.1 Definition | |
      2. 2.1.2 Scope of the study | | |
        1. 2.1.2.1 Research Objective | | |
        2. 2.1.2.2 Assumption | | |
        3. 2.1.2.3 Limitations |
    2. 2.2 RESEARCH METHODOLOGY | |
      1. 2.2.1 Overview | |
      2. 2.2.2 Data Mining | |
      3. 2.2.3 Secondary Research | |
      4. 2.2.4 Primary Research | | |
        1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
        2. 2.2.4.2 Breakdown of Primary Respondents | |
      5. 2.2.5 Forecasting Model | |
      6. 2.2.6 Market Size Estimation | | |
        1. 2.2.6.1 Bottom-Up Approach | | |
        2. 2.2.6.2 Top-Down Approach | |
      7. 2.2.7 Data Triangulation | |
      8. 2.2.8 Validation 3
  3. SECTION III: QUALITATIVE ANALYSIS |
    1. 3.1 MARKET DYNAMICS | |
      1. 3.1.1 Overview | |
      2. 3.1.2 Drivers | |
      3. 3.1.3 Restraints | |
      4. 3.1.4 Opportunities |
    2. 3.2 MARKET FACTOR ANALYSIS | |
      1. 3.2.1 Value chain Analysis | |
      2. 3.2.2 Porter's Five Forces Analysis | | |
        1. 3.2.2.1 Bargaining Power of Suppliers | | |
        2. 3.2.2.2 Bargaining Power of Buyers | | |
        3. 3.2.2.3 Threat of New Entrants | | |
        4. 3.2.2.4 Threat of Substitutes | | |
        5. 3.2.2.5 Intensity of Rivalry | |
      3. 3.2.3 COVID-19 Impact Analysis | | |
        1. 3.2.3.1 Market Impact Analysis | | |
        2. 3.2.3.2 Regional Impact | | |
        3. 3.2.3.3 Opportunity and Threat Analysis 4
  4. SECTION IV: QUANTITATIVE ANALYSIS |
    1. 4.1 Healthcare, BY Drug Class (USD Billion) | |
      1. 4.1.1 Bronchodilators | |
      2. 4.1.2 Corticosteroids | |
      3. 4.1.3 Combination Drugs | |
      4. 4.1.4 Leukotriene Modifiers |
    2. 4.2 Healthcare, BY Route of Administration (USD Billion) | |
      1. 4.2.1 Inhalation | |
      2. 4.2.2 Oral | |
      3. 4.2.3 Injection | |
      4. 4.2.4 Nasal |
    3. 4.3 Healthcare, BY Application (USD Billion) | |
      1. 4.3.1 Asthma | |
      2. 4.3.2 Chronic Obstructive Pulmonary Disease | |
      3. 4.3.3 Allergic Rhinitis | |
      4. 4.3.4 Pulmonary Hypertension |
    4. 4.4 Healthcare, BY Patient Group (USD Billion) | |
      1. 4.4.1 Adult | |
      2. 4.4.2 Pediatric | |
      3. 4.4.3 Geriatric |
    5. 4.5 Healthcare, BY Region (USD Billion) | |
      1. 4.5.1 North America | | |
        1. 4.5.1.1 US | | |
        2. 4.5.1.2 Canada | |
      2. 4.5.2 Europe | | |
        1. 4.5.2.1 Germany | | |
        2. 4.5.2.2 UK | | |
        3. 4.5.2.3 France | | |
        4. 4.5.2.4 Russia | | |
        5. 4.5.2.5 Italy | | |
        6. 4.5.2.6 Spain | | |
        7. 4.5.2.7 Rest of Europe | |
      3. 4.5.3 APAC | | |
        1. 4.5.3.1 China | | |
        2. 4.5.3.2 India | | |
        3. 4.5.3.3 Japan | | |
        4. 4.5.3.4 South Korea | | |
        5. 4.5.3.5 Malaysia | | |
        6. 4.5.3.6 Thailand | | |
        7. 4.5.3.7 Indonesia | | |
        8. 4.5.3.8 Rest of APAC | |
      4. 4.5.4 South America | | |
        1. 4.5.4.1 Brazil | | |
        2. 4.5.4.2 Mexico | | |
        3. 4.5.4.3 Argentina | | |
        4. 4.5.4.4 Rest of South America | |
      5. 4.5.5 MEA | | |
        1. 4.5.5.1 GCC Countries | | |
        2. 4.5.5.2 South Africa | | |
        3. 4.5.5.3 Rest of MEA 5
  5. SECTION V: COMPETITIVE ANALYSIS |
    1. 5.1 Competitive Landscape | |
      1. 5.1.1 Overview | |
      2. 5.1.2 Competitive Analysis | |
      3. 5.1.3 Market share Analysis | |
      4. 5.1.4 Major Growth Strategy in the Healthcare | |
      5. 5.1.5 Competitive Benchmarking | |
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
      7. 5.1.7 Key developments and growth strategies | | |
        1. 5.1.7.1 New Product Launch/Service Deployment | | |
        2. 5.1.7.2 Merger & Acquisitions | | |
        3. 5.1.7.3 Joint Ventures | |
      8. 5.1.8 Major Players Financial Matrix | | |
        1. 5.1.8.1 Sales and Operating Income | | |
        2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
    2. 5.2 Company Profiles | |
      1. 5.2.1 GlaxoSmithKline (GB) | | |
        1. 5.2.1.1 Financial Overview | | |
        2. 5.2.1.2 Products Offered | | |
        3. 5.2.1.3 Key Developments | | |
        4. 5.2.1.4 SWOT Analysis | | |
        5. 5.2.1.5 Key Strategies | |
      2. 5.2.2 Boehringer Ingelheim (DE) | | |
        1. 5.2.2.1 Financial Overview | | |
        2. 5.2.2.2 Products Offered | | |
        3. 5.2.2.3 Key Developments | | |
        4. 5.2.2.4 SWOT Analysis | | |
        5. 5.2.2.5 Key Strategies | |
      3. 5.2.3 AstraZeneca (GB) | | |
        1. 5.2.3.1 Financial Overview | | |
        2. 5.2.3.2 Products Offered | | |
        3. 5.2.3.3 Key Developments | | |
        4. 5.2.3.4 SWOT Analysis | | |
        5. 5.2.3.5 Key Strategies | |
      4. 5.2.4 Novartis (CH) | | |
        1. 5.2.4.1 Financial Overview | | |
        2. 5.2.4.2 Products Offered | | |
        3. 5.2.4.3 Key Developments | | |
        4. 5.2.4.4 SWOT Analysis | | |
        5. 5.2.4.5 Key Strategies | |
      5. 5.2.5 Teva Pharmaceutical Industries (IL) | | |
        1. 5.2.5.1 Financial Overview | | |
        2. 5.2.5.2 Products Offered | | |
        3. 5.2.5.3 Key Developments | | |
        4. 5.2.5.4 SWOT Analysis | | |
        5. 5.2.5.5 Key Strategies | |
      6. 5.2.6 Merck & Co. (US) | | |
        1. 5.2.6.1 Financial Overview | | |
        2. 5.2.6.2 Products Offered | | |
        3. 5.2.6.3 Key Developments | | |
        4. 5.2.6.4 SWOT Analysis | | |
        5. 5.2.6.5 Key Strategies | |
      7. 5.2.7 Sanofi (FR) | | |
        1. 5.2.7.1 Financial Overview | | |
        2. 5.2.7.2 Products Offered | | |
        3. 5.2.7.3 Key Developments | | |
        4. 5.2.7.4 SWOT Analysis | | |
        5. 5.2.7.5 Key Strategies | |
      8. 5.2.8 Roche (CH) | | |
        1. 5.2.8.1 Financial Overview | | |
        2. 5.2.8.2 Products Offered | | |
        3. 5.2.8.3 Key Developments | | |
        4. 5.2.8.4 SWOT Analysis | | |
        5. 5.2.8.5 Key Strategies | |
      9. 5.2.9 Pfizer (US) | | |
        1. 5.2.9.1 Financial Overview | | |
        2. 5.2.9.2 Products Offered | | |
        3. 5.2.9.3 Key Developments | | |
        4. 5.2.9.4 SWOT Analysis | | |
        5. 5.2.9.5 Key Strategies |
    3. 5.3 Appendix | |
      1. 5.3.1 References | |
      2. 5.3.2 Related Reports 6 LIST OF FIGURES |
    4. 6.1 MARKET SYNOPSIS |
    5. 6.2 NORTH AMERICA MARKET ANALYSIS |
    6. 6.3 US MARKET ANALYSIS BY DRUG CLASS |
    7. 6.4 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    8. 6.5 US MARKET ANALYSIS BY APPLICATION |
    9. 6.6 US MARKET ANALYSIS BY PATIENT GROUP |
    10. 6.7 CANADA MARKET ANALYSIS BY DRUG CLASS |
    11. 6.8 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    12. 6.9 CANADA MARKET ANALYSIS BY APPLICATION |
    13. 6.10 CANADA MARKET ANALYSIS BY PATIENT GROUP |
    14. 6.11 EUROPE MARKET ANALYSIS |
    15. 6.12 GERMANY MARKET ANALYSIS BY DRUG CLASS |
    16. 6.13 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    17. 6.14 GERMANY MARKET ANALYSIS BY APPLICATION |
    18. 6.15 GERMANY MARKET ANALYSIS BY PATIENT GROUP |
    19. 6.16 UK MARKET ANALYSIS BY DRUG CLASS |
    20. 6.17 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    21. 6.18 UK MARKET ANALYSIS BY APPLICATION |
    22. 6.19 UK MARKET ANALYSIS BY PATIENT GROUP |
    23. 6.20 FRANCE MARKET ANALYSIS BY DRUG CLASS |
    24. 6.21 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    25. 6.22 FRANCE MARKET ANALYSIS BY APPLICATION |
    26. 6.23 FRANCE MARKET ANALYSIS BY PATIENT GROUP |
    27. 6.24 RUSSIA MARKET ANALYSIS BY DRUG CLASS |
    28. 6.25 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    29. 6.26 RUSSIA MARKET ANALYSIS BY APPLICATION |
    30. 6.27 RUSSIA MARKET ANALYSIS BY PATIENT GROUP |
    31. 6.28 ITALY MARKET ANALYSIS BY DRUG CLASS |
    32. 6.29 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    33. 6.30 ITALY MARKET ANALYSIS BY APPLICATION |
    34. 6.31 ITALY MARKET ANALYSIS BY PATIENT GROUP |
    35. 6.32 SPAIN MARKET ANALYSIS BY DRUG CLASS |
    36. 6.33 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    37. 6.34 SPAIN MARKET ANALYSIS BY APPLICATION |
    38. 6.35 SPAIN MARKET ANALYSIS BY PATIENT GROUP |
    39. 6.36 REST OF EUROPE MARKET ANALYSIS BY DRUG CLASS |
    40. 6.37 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    41. 6.38 REST OF EUROPE MARKET ANALYSIS BY APPLICATION |
    42. 6.39 REST OF EUROPE MARKET ANALYSIS BY PATIENT GROUP |
    43. 6.40 APAC MARKET ANALYSIS |
    44. 6.41 CHINA MARKET ANALYSIS BY DRUG CLASS |
    45. 6.42 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    46. 6.43 CHINA MARKET ANALYSIS BY APPLICATION |
    47. 6.44 CHINA MARKET ANALYSIS BY PATIENT GROUP |
    48. 6.45 INDIA MARKET ANALYSIS BY DRUG CLASS |
    49. 6.46 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    50. 6.47 INDIA MARKET ANALYSIS BY APPLICATION |
    51. 6.48 INDIA MARKET ANALYSIS BY PATIENT GROUP |
    52. 6.49 JAPAN MARKET ANALYSIS BY DRUG CLASS |
    53. 6.50 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    54. 6.51 JAPAN MARKET ANALYSIS BY APPLICATION |
    55. 6.52 JAPAN MARKET ANALYSIS BY PATIENT GROUP |
    56. 6.53 SOUTH KOREA MARKET ANALYSIS BY DRUG CLASS |
    57. 6.54 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    58. 6.55 SOUTH KOREA MARKET ANALYSIS BY APPLICATION |
    59. 6.56 SOUTH KOREA MARKET ANALYSIS BY PATIENT GROUP |
    60. 6.57 MALAYSIA MARKET ANALYSIS BY DRUG CLASS |
    61. 6.58 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    62. 6.59 MALAYSIA MARKET ANALYSIS BY APPLICATION |
    63. 6.60 MALAYSIA MARKET ANALYSIS BY PATIENT GROUP |
    64. 6.61 THAILAND MARKET ANALYSIS BY DRUG CLASS |
    65. 6.62 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    66. 6.63 THAILAND MARKET ANALYSIS BY APPLICATION |
    67. 6.64 THAILAND MARKET ANALYSIS BY PATIENT GROUP |
    68. 6.65 INDONESIA MARKET ANALYSIS BY DRUG CLASS |
    69. 6.66 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    70. 6.67 INDONESIA MARKET ANALYSIS BY APPLICATION |
    71. 6.68 INDONESIA MARKET ANALYSIS BY PATIENT GROUP |
    72. 6.69 REST OF APAC MARKET ANALYSIS BY DRUG CLASS |
    73. 6.70 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    74. 6.71 REST OF APAC MARKET ANALYSIS BY APPLICATION |
    75. 6.72 REST OF APAC MARKET ANALYSIS BY PATIENT GROUP |
    76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
    77. 6.74 BRAZIL MARKET ANALYSIS BY DRUG CLASS |
    78. 6.75 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    79. 6.76 BRAZIL MARKET ANALYSIS BY APPLICATION |
    80. 6.77 BRAZIL MARKET ANALYSIS BY PATIENT GROUP |
    81. 6.78 MEXICO MARKET ANALYSIS BY DRUG CLASS |
    82. 6.79 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    83. 6.80 MEXICO MARKET ANALYSIS BY APPLICATION |
    84. 6.81 MEXICO MARKET ANALYSIS BY PATIENT GROUP |
    85. 6.82 ARGENTINA MARKET ANALYSIS BY DRUG CLASS |
    86. 6.83 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    87. 6.84 ARGENTINA MARKET ANALYSIS BY APPLICATION |
    88. 6.85 ARGENTINA MARKET ANALYSIS BY PATIENT GROUP |
    89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY DRUG CLASS |
    90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY APPLICATION |
    92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY PATIENT GROUP |
    93. 6.90 MEA MARKET ANALYSIS |
    94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY DRUG CLASS |
    95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY APPLICATION |
    97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY PATIENT GROUP |
    98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY DRUG CLASS |
    99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY APPLICATION |
    101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY PATIENT GROUP |
    102. 6.99 REST OF MEA MARKET ANALYSIS BY DRUG CLASS |
    103. 6.100 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION |
    104. 6.101 REST OF MEA MARKET ANALYSIS BY APPLICATION |
    105. 6.102 REST OF MEA MARKET ANALYSIS BY PATIENT GROUP |
    106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
    107. 6.104 RESEARCH PROCESS OF MRFR |
    108. 6.105 DRO ANALYSIS OF HEALTHCARE |
    109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
    110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
    111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
    112. 6.109 HEALTHCARE, BY DRUG CLASS, 2024 (% SHARE) |
    113. 6.110 HEALTHCARE, BY DRUG CLASS, 2024 TO 2035 (USD Billion) |
    114. 6.111 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE) |
    115. 6.112 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion) |
    116. 6.113 HEALTHCARE, BY APPLICATION, 2024 (% SHARE) |
    117. 6.114 HEALTHCARE, BY APPLICATION, 2024 TO 2035 (USD Billion) |
    118. 6.115 HEALTHCARE, BY PATIENT GROUP, 2024 (% SHARE) |
    119. 6.116 HEALTHCARE, BY PATIENT GROUP, 2024 TO 2035 (USD Billion) |
    120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
    121. 7.1 LIST OF ASSUMPTIONS | |
      1. 7.1.1 |
    122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.2.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.2.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.2.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.2.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.3.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.3.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.3.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.3.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.4.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.4.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.4.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.4.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.5.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.5.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.5.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.5.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.6.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.6.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.6.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.6.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.7.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.7.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.7.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.7.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.8.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.8.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.8.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.8.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.9.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.9.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.9.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.9.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.10.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.10.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.10.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.10.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.11.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.11.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.11.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.11.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.12.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.12.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.12.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.12.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.13.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.13.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.13.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.13.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.14.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.14.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.14.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.14.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.15.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.15.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.15.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.15.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.16.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.16.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.16.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.16.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.17.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.17.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.17.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.17.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.18.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.18.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.18.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.18.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.19.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.19.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.19.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.19.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.20.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.20.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.20.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.20.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.21.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.21.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.21.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.21.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.22.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.22.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.22.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.22.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.23.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.23.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.23.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.23.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.24.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.24.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.24.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.24.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.25.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.25.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.25.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.25.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.26.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.26.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.26.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.26.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.27.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.27.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.27.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.27.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.28.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.28.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.28.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.28.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.29.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.29.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.29.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.29.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
      1. 7.30.1 BY DRUG CLASS, 2025-2035 (USD Billion) | |
      2. 7.30.2 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion) | |
      3. 7.30.3 BY APPLICATION, 2025-2035 (USD Billion) | |
      4. 7.30.4 BY PATIENT GROUP, 2025-2035 (USD Billion) |
    151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
      1. 7.31.1 |
    152. 7.32 ACQUISITION/PARTNERSHIP | |

Asthma COPD Drugs Market Segmentation

Asthma COPD Drugs Market By Drug Class (USD Billion, 2025-2035)

  • Bronchodilators
  • Corticosteroids
  • Combination Drugs
  • Leukotriene Modifiers

Asthma COPD Drugs Market By Route of Administration (USD Billion, 2025-2035)

  • Inhalation
  • Oral
  • Injection
  • Nasal

Asthma COPD Drugs Market By Application (USD Billion, 2025-2035)

  • Asthma
  • Chronic Obstructive Pulmonary Disease
  • Allergic Rhinitis
  • Pulmonary Hypertension

Asthma COPD Drugs Market By Patient Group (USD Billion, 2025-2035)

  • Adult
  • Pediatric
  • Geriatric

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.